Affiliation:
1. Tissue Engineering Research Group Department of Anatomy & Regenerative Medicine Royal College of Surgeons in Ireland (RCSI) 123 St. Stephen's Green D02YN77 Dublin 2 Ireland
2. Advanced Materials and Bioengineering Research (AMBER) Centre, RCSI 123 St Stephen's Green D02YN77 Dublin 2 Ireland
3. Trinity Centre for Biomedical Engineering Trinity College Dublin D02R590 Dublin 2 Ireland
Abstract
Spinal cord injury (SCI) is a devastating traumatic injury often causing permanent loss of function. The challenge of treating SCI stems from the development of a complex pathophysiology at the site of injury, involving multiple biochemical cascades, widespread inflammation, blood supply interruption, inhibitory scar formation, and poor regrowth of injured axons. Clinical options are limited to surgical stabilization and attempt to ameliorate secondary damage following injury. Gene therapy has significant potential to tackle multiple aspects of SCI and improve functional outcomes. The emergence of a diverse array of biomaterial‐based nonviral nanoparticle vectors capable of delivering gene‐modifying nucleic acids offers the potential to improve the efficiency and specificity of genetic cargos for spinal cord regeneration. In this review, the progress that has been made in the field of SCI repair and the different types of nanoparticles and nucleic acid cargoes that have been used are outlined, placing a particular focus on the different cell types and pathways targeted. While many challenges remain, a perspective on the future of the field of nanoparticle‐mediated gene delivery for SCI is provided, including using biomaterial scaffolds engineered specifically for SCI to deliver gene therapeutics and the exciting opportunities that exist in the post‐COVID landscape.